Bill
Bill > HR4866
US HR4866
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2020
summary
Introduced
10/28/2019
10/28/2019
In Committee
07/15/2020
07/15/2020
Crossed Over
09/22/2020
09/22/2020
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
AN ACT To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.
AI Summary
This bill amends the 21st Century Cures Act to establish National Centers of Excellence in Continuous Pharmaceutical Manufacturing. The bill directs the Secretary of Health and Human Services, acting through the FDA Commissioner, to designate institutions of higher education that meet certain criteria as National Centers of Excellence to support the advancement and development of continuous manufacturing. The bill provides funding for the designated centers to study and recommend improvements to continuous manufacturing, and requires the Secretary to report annually to Congress on the centers' activities and findings. The bill also requires the Secretary to develop a report on the FDA's long-term vision for supporting continuous manufacturing in pharmaceutical development and regulation.
Committee Categories
Business and Industry, Health and Social Services
Sponsors (3)
Last Action
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 09/22/2020)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
Loading...